Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors

PURPOSE: To conduct a first-in-human phase I study to determine the dose-limiting toxicities (DLT), characterize the pharmacokinetic profile, and document the antitumor activity of IPI-926, a new chemical entity that inhibits the Hedgehog pathway (HhP). EXPERIMENTAL DESIGN: Patients with solid tumor...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Jimeno, Antonio, Weiss, Glen J., Miller, Wilson H., Gettinger, Scott, Eigl, Bernard J.C., Chang, Anne Lynne S., Dunbar, Joi, Devens, Shannon, Faia, Kerrie, Skliris, Georgios, Kutok, Jeff, Lewis, Karl D., Tibes, Raoul, Sharfman, William H., Ross, Robert W., Rudin, Charles M.
Formato: Artigo
Idioma:Inglês
Publicado: 2013
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3694426/
https://ncbi.nlm.nih.gov/pubmed/23575478
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-3654
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares